Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population

DA. van Riet-Nales, B. van den Bemt, D. van Bodegom, F. Cerreta, B. Dooley, D. Eggenschwyler, B. Hirschlérova, PAF. Jansen, F. Karapinar-Çarkit, A. Moran, J. Span, S. Stegemann, K. Sundberg

. 2022 ; 88 (4) : 1500-1514. [pub] 20220209

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019401

Older people are often affected by impaired organ and bodily functions resulting in multimorbidity and polypharmacy, turning them into the main user group of many medicines. Very often, medicines have not specifically been developed for older people, causing practical medication problems for them like limited availability of easy to swallow formulations, easy to open packaging and dosing instructions for enteral administration. In 2020, the European Medicines Agency (EMA) published a reflection paper 'Pharmaceutical development of medicines for use in the older population', which discusses how the emerging needs of an ageing European population can be addressed by medicines regulation. The paper intends to help industry to better consider the needs of older people during pharmaceutical/clinical medicines development by summarising data on the most relevant topics, providing early suggestions on how to move forward and prompting expert discussions and studies into knowledge gaps. Topics include patient acceptability, (dis)advantages of an administration route, formulation, dosage form, packaging, dosing device and user instruction. While the paper is directed at older people and the pharmaceutical industry, the reflections are also relevant to younger patients with similar disease-related needs and of value to other stakeholders parties, e.g., healthcare professionals, academics, patients and caregivers, as the paper makes clear what can be expected from industry and where collaborative work is needed. This commentary provides an overview of the different steps in the development of the reflection paper, discusses points considered most controversial and/or subject to (multidisciplinary) expert discussions and indicates their value for real world clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019401
003      
CZ-PrNML
005      
20220804135624.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bcp.15207 $2 doi
035    __
$a (PubMed)35141926
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a van Riet-Nales, Diana A $u Department of Chemical Pharmaceutical Assessments, Medicines Evaluation Board (MEB), Utrecht, Netherlands $1 https://orcid.org/0000000249024519
245    10
$a Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population / $c DA. van Riet-Nales, B. van den Bemt, D. van Bodegom, F. Cerreta, B. Dooley, D. Eggenschwyler, B. Hirschlérova, PAF. Jansen, F. Karapinar-Çarkit, A. Moran, J. Span, S. Stegemann, K. Sundberg
520    9_
$a Older people are often affected by impaired organ and bodily functions resulting in multimorbidity and polypharmacy, turning them into the main user group of many medicines. Very often, medicines have not specifically been developed for older people, causing practical medication problems for them like limited availability of easy to swallow formulations, easy to open packaging and dosing instructions for enteral administration. In 2020, the European Medicines Agency (EMA) published a reflection paper 'Pharmaceutical development of medicines for use in the older population', which discusses how the emerging needs of an ageing European population can be addressed by medicines regulation. The paper intends to help industry to better consider the needs of older people during pharmaceutical/clinical medicines development by summarising data on the most relevant topics, providing early suggestions on how to move forward and prompting expert discussions and studies into knowledge gaps. Topics include patient acceptability, (dis)advantages of an administration route, formulation, dosage form, packaging, dosing device and user instruction. While the paper is directed at older people and the pharmaceutical industry, the reflections are also relevant to younger patients with similar disease-related needs and of value to other stakeholders parties, e.g., healthcare professionals, academics, patients and caregivers, as the paper makes clear what can be expected from industry and where collaborative work is needed. This commentary provides an overview of the different steps in the development of the reflection paper, discusses points considered most controversial and/or subject to (multidisciplinary) expert discussions and indicates their value for real world clinical practice.
650    _2
$a senioři $7 D000368
650    _2
$a vyvíjení léků $7 D000076722
650    12
$a farmaceutický průmysl $7 D004345
650    _2
$a lidé $7 D006801
650    _2
$a multimorbidita $7 D000076322
650    _2
$a léčivé přípravky $7 D004364
650    12
$a polypharmacy $7 D019338
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a van den Bemt, Bart $u Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands $u Department of Pharmacy, Radboud University Medical Center, Nijmegen, Netherlands $1 https://orcid.org/0000000285609514
700    1_
$a van Bodegom, David $u Public Health and Primary Care, Leyden Academy on Vitality and Ageing, Leiden, Netherlands $u Department Public Health and Primary Care, Leiden University Medical Centre, Leiden, Netherlands
700    1_
$a Cerreta, Francesca $u Scientific Evidence Generation Department, Human Medicines Division, European Medicines Agency, Amsterdam, Netherlands $1 https://orcid.org/0000000193167800
700    1_
$a Dooley, Brian $u Quality and Safety of Medicines Department, Human Medicines Division, European Medicines Agency, Amsterdam, Netherlands
700    1_
$a Eggenschwyler, Doris $u Quality Department, Swissmedic, Basel, Switzerland
700    1_
$a Hirschlérova, Blanka $u Department of Pharmaceutical Assessment of Chemical and Herbal Products, State Institute for Drug Control (SUKL), Prague, Czech Republic
700    1_
$a Jansen, Paul A F $u Department of Chemical Pharmaceutical Assessments, Medicines Evaluation Board (MEB), Utrecht, Netherlands $u Geriatric Department, University Medical Center, Utrecht, Netherlands $u Expertise Centre Pharmacotherapy in Old Persons (EPHOR), Utrecht, Netherlands
700    1_
$a Karapinar-Çarkit, Fatma $u Department of Clinical Pharmacy, OLVG Hospital, Amsterdam, Netherlands $1 https://orcid.org/0000000230779663
700    1_
$a Moran, Abigail $u Medicines and Healthcare Products Regulatory Agency, London, UK
700    1_
$a Span, Jan $u Department of Chemical Pharmaceutical Assessments, Medicines Evaluation Board (MEB), Utrecht, Netherlands
700    1_
$a Stegemann, Sven $u Institute of Process and Particle Engineering, Graz University of Technology, Graz, Austria $1 https://orcid.org/0000000343601714
700    1_
$a Sundberg, Katarina $u Department of Pharmaceutics and Biotechnology, Swedish Medical Products Agency (MPA), Uppsala, Sweden
773    0_
$w MED00000858 $t British journal of clinical pharmacology $x 1365-2125 $g Roč. 88, č. 4 (2022), s. 1500-1514
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35141926 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135617 $b ABA008
999    __
$a ok $b bmc $g 1822829 $s 1170644
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 88 $c 4 $d 1500-1514 $e 20220209 $i 1365-2125 $m British journal of clinical pharmacology $n Br J Clin Pharmacol $x MED00000858
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace